|Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations|
KA Phillips, IM Collins, RL Milne, SA McLachlan, M Friedlander, M Hickey, ...
Human Reproduction 31 (5), 1126-1132, 2016
|Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers|
IM Collins, RL Milne, PC Weideman, SA McLachlan, ML Friedlander, ...
Med J Aust 199 (10), 680-3, 2013
|Do BRCA1 and BRCA2 Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuningham Foundation …|
IM Collins, RL Milne, SA McLachlan, M Friedlander, M Hickey, ...
Journal of clinical oncology 31 (31), 3920-3925, 2013
|Assessing and managing breast cancer risk: Clinicians' current practice and future needs|
IM Collins, E Steel, GB Mann, JD Emery, A Bickerstaffe, A Trainer, ...
The Breast 23 (5), 644-650, 2014
|The tubal hypothesis of ovarian cancer: caution needed|
IM Collins, SM Domchek, DG Huntsman, G Mitchell
The lancet oncology 12 (12), 1089-1091, 2011
|iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management|
IM Collins, A Bickerstaffe, T Ranaweera, S Maddumarachchi, L Keogh, ...
Breast cancer research and treatment 156 (1), 171-182, 2016
|Women’s preferences for selective estrogen reuptake modulators: an investigation using the time trade-off technique|
AF Ralph, B Ager, ML Bell, IM Collins, L Andrews, K Tucker, N O’Reilly, ...
SpringerPlus 3 (1), 264, 2014
|Women's preferences for selective estrogen reuptake modulators: an investigation using protection motivation theory|
AF Ralph, B Ager, ML Bell, IM Collins, L Andrews, K Tucker, KA Phillips, ...
Patient education and counseling 96 (1), 106-112, 2014
|Strategies for fertility preservation after chemotherapy awareness among Irish Cancer specialists|
IM Collins, MJ Kennedy
Irish Medical Journal, 2011
|Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease?|
KA Phillips, EJ Steel, I Collins, J Emery, M Pirotta, GB Mann, P Butow, ...
Australian journal of primary health 22 (3), 255-261, 2016
|Consumer and clinician perspectives on personalising breast cancer prevention information|
LA Keogh, E Steel, P Weideman, P Butow, IM Collins, JD Emery, ...
The Breast 43, 39-47, 2019
|Carboplatin Dosing in Ovarian Cancer: Problems and Pitfalls|
IM Collins, R Roberts-Thomson, D Faulkner, D Rischin, M Friedlander, ...
International Journal of Gynecological Cancer 21 (7), 1213, 2011
|Terminology and Details of the Diagnostic Process for Testis Cancer|
SS Connolly, PJA Daly, MSJ Floyd Jr, IM Collins, R Grainger, JA Thornhill
The Journal of urology 185 (3), 876-880, 2011
|Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor|
IM Collins, P Beddy, KJ O'BYRNE
Acta oncologica 49 (6), 872-874, 2010
|Clinical Decision Aids in Colon Cancer; A Comparison of Two Predictive Nomograms|
IM Collins, F Kelleher, C Stuart, M Collins, J Kennedy
Clinical Colorectal Cancer, 2011
|Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool|
KA Phillips, Y Liao, RL Milne, RJ MacInnis, IM Collins, R Buchsbaum, ...
JNCI Cancer Spectrum 3 (4), pkz066, 2019
|Electronic clinical decision support systems attitudes and barriers to use in the oncology setting.|
IM Collins, O Breathnach, P Felle
Irish Journal of Medical Science, 2012
|A Role for IGF-1R–Targeted Therapies in Small-Cell Lung Cancer?|
K Gately, I Collins, L Forde, B Al-Alao, V Young, M Gerg, F Feuerhake, ...
Clinical Lung Cancer 12 (1), 38-42, 2011
|Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular …|
C Murphy, A Muscat, D Ashley, V Mukaro, L West, Y Liao, D Chisanga, ...
PloS one 14 (2), e0210891, 2019
|Novel Approaches to Treatment of Leiomyosarcomas|
IM Collins, DM Thomas
Current oncology reports, 1-7, 2011